Ingevity (NGVT) has drawn fresh attention after recent share price moves, prompting investors to reassess how its current valuation lines up with fundamentals such as segment mix, recent returns and profitability trends.

The latest move takes Ingevity's share price to $77.12, with a 1-month share price return of 11.88% and a year-to-date share price return of 28.34%. The 1-year total shareholder return of 77.86% contrasts with a 5-year total shareholder return that is slightly negative, suggesting strong recent momentum from a weaker longer-term base.

If you are looking beyond Ingevity for other opportunities benefiting from similar interest in industrial and materials exposure, this could be a good moment to check out 20 top founder-led companies

With Ingevity now at $77.12 and recent returns running ahead of its slightly negative 5-year record, investors face a key question: is the stock still undervalued, or is the market already pricing in future growth?

Most Popular Narrative: 9.8% Undervalued

Based on the most followed valuation narrative, Ingevity's fair value of $85.50 sits above the last close at $77.12, which frames the stock as modestly underpriced against those assumptions.

Accelerated portfolio repositioning and the advanced-stage divestiture of non-core, lower-margin businesses (Industrial Specialties and CTO refinery) are expected to drive a step-change in margin profile, enabling greater focus and capital allocation toward higher-growth, value-added specialty chemicals, supporting both revenue quality and sustained EBITDA margin improvement.

Want to see what turns a loss-making Ingevity into a high margin story with a lower future earnings multiple baked in? The narrative leans heavily on profit recovery, shrinking share count and a specific discount rate to support that $85.50 figure.

Result: Fair Value of $85.50 (UNDERVALUED)

However, this upbeat Ingevity narrative can be knocked off course if the Advanced Polymer Technologies unit continues to struggle with weaker demand or if tariff related pressures persist and weigh on margins.

Another View: What Multiples Say About Ingevity

While the popular Ingevity narrative leans on a fair value of $85.50, the market is currently paying a P/S of 2.3x, compared with 1.1x for the US Chemicals industry and a peer average of 1.3x. The fair ratio is 1.4x, which suggests investors are accepting a richer entry point and less margin for error if the story does not play out as expected.

That gap raises a simple question for you as an investor: is the higher P/S a price worth paying for this particular recovery and portfolio reshaping story, or does it tilt the balance of risk and reward too far?

Next Steps

Given the mix of optimism and concern around Ingevity, this is a good moment to move quickly, review the data yourself and decide where you stand by starting with the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Ingevity?

If Ingevity's story has you thinking about what else could be worth your attention, use this momentum to widen your watchlist and compare different types of opportunities.

• Target quality at a discount by scanning companies that trade below what their fundamentals suggest using the 44 high quality undervalued stocks.
• Strengthen your portfolio's foundation by reviewing stocks identified in the solid balance sheet and fundamentals stocks screener (48 results).
• Hunt for lesser-known potential opportunities that others might be overlooking through the screener containing 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.